Literature DB >> 21104349

Successful perioperative management for a breast cancer patient with Bernard-Soulier syndrome.

Riki Okita1, Jun Hihara, Kazuo Konishi, Akihiko Osaki, Kingo Fujimura.   

Abstract

We herein report the first case of a Bernard-Soulier syndrome (BSS) patient undergoing a surgical procedure for breast cancer. BSS is a rare hereditary thrombocytopathy associated with defects of the platelet glycoprotein complex glycoprotein Ib/V/IX and characterized by large platelets, thrombocytopenia, and severe bleeding symptoms. Because of the rarity of BSS, there are as yet no defined protocols for the perioperative management, which can be very complex and challenging in patients with coagulopathies, in particular BSS. In this case we successfully performed both an interventional examination as well as mastectomy with axillary lymph node dissection, under the preventive and intermittent transfusion of platelets. No intra- or postoperative bleeding complications occurred. Unfortunately, the patient was diagnosed as having metastatic disease involving liver, lungs, and bones 10 months after the surgery. She had received 1st, 2nd, and 3rd line chemotherapy without severe adverse events. However, gastrointestinal bleeding appeared after she was treated with 4th line chemotherapy. Finally, she succumbed 22 months after the breast surgery.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21104349     DOI: 10.1007/s12282-010-0241-6

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  2 in total

1.  Utilization of paravertebral nerve blocks as part of a multimodal analgesic regimen in a patient with Bernard-Soulier syndrome undergoing a Nuss procedure.

Authors:  Elird Bojaxhi; Arun Kalava; Roy Greengrass
Journal:  Rom J Anaesth Intensive Care       Date:  2016-04

Review 2.  Platelet transfusion for patients with platelet dysfunction: effectiveness, mechanisms, and unanswered questions.

Authors:  Robert H Lee; Raj S Kasthuri; Wolfgang Bergmeier
Journal:  Curr Opin Hematol       Date:  2020-11       Impact factor: 3.218

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.